Market Research Report - 241565
Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts
|Published by||Greystone Research Associates|
|Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts|
|Published: May 21, 2012||Content info:||
This publication has been discontinued on February 26, 2013.
Greystone Research Associates is pleased to announce the publication of a new market study. Non-Insulin Diabetes Management: Products, Players, Markets and Forecasts is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector.
The study is designed to provide drug company decision makers, drug developers, healthcare marketers, and supply chain participants with a detailed understanding of the products, markets and commercial opportunities for diabetes drug therapeutics that do not derive from the administration of insulins or insulin analogs. Provider organization business managers, healthcare administrators and investors will also benefit from this study.
The diabetes market is changing. The convergence of environmental factors, lifestyle factors and increased patient longevity are driving double-digit growth projections for the incidence of non-insulin dependent (Type 2) diabetes globally. Type 2 diabetes accounts for about 90% of all diagnosed cases of diabetes and is increasingly being diagnosed in children and adolescents. There are eight drug classes, analyzed in this report, with proven efficacy for aiding in glycemic control in this patient population. Because of the size and business potential of this market, pipeline activity is high. In addition to derivative products and products that combine approved APIs in a single dosage form, drugs based on newer chemistries and mechanisms that include amylin analogs and GLP-1 drugs have been introduced. Globally, revenues of drugs for managing Type 2 diabetes will grow by 14% between 2011 and 2016. Safety issues associated with post-launch-reported events will continue to be a major concern for market participants.
Greystone Associates is a medical technology consulting firm focused on the areas of medical market strategy, product commercialization, venture development, and market research. We assist medical and healthcare market participants in achieving their business objectives through the creation of detailed development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Our market research publications are designed, researched and written to provide timely and insightful information and data on focused market segments, with the aim of providing market participants with the essential knowledge to refine and execute their marketing plans and financial targets.